InDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen Characterization
USA - English
Share this article
Share this article
BOULDER, Colorado, Jan. 19, 2021 /PRNewswire/ InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray
® Measles and Rubella (MR) antigen quantification kit.
Funded by the Bill and Melinda Gates Foundation with the goal of reducing the time and cost of manufacturing for these life-saving vaccines, InDevR s VaxArray MR kit leverages the company s established VaxArray
® platform to deliver a rapid quantitative analysis of specific measles and rubella antigens. The VaxArray MR kit provides a precise measure of antigen content in 5 hours, which is a fraction of the time needed for the traditional 10-14-day tissue culture infectious dose measurement. The high accuracy and preci